SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as discussions revolve around the potential of its MASH drug, Pemvidutide, following positive AI-driven analysis of trial data; the community anticipates upcoming 48-week results and a meeting with the FDA. Some are speculating about potential for accelerated approval or a buyout, while others urge caution, pointing to past data and potential dilution risks. Bullish sentiment is fueled by comparisons to other high-performing stocks in the sector.

SAIHEAT Ltd. engages in the operation of cryptocurrency mining. It operates Bitcoin for its own account and provides full suite of services, purchase of mining machines, hosting service, and mining pool. The company was founded by Risheng Li on February 2, 2021, and is headquartered in Singapore.

SAIHEAT Ltd. - Ordinary Shares - Class A

SAIHEAT Ltd

SAIH is trending due to community excitement around its low float and potential for a significant breakout, with many drawing comparisons to other recent parabolic runners. Discussions center on breaking key resistance levels that could trigger a rapid price increase, and its possible connection to AI and data centers.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR is trending due to positive sentiment around a recent Phase 3 clinical study, although opinions are split on whether this will be a long-term catalyst or a short-lived pump, as some traders discuss an upcoming share offering and reverse split. Community members are weighing the potential for a short squeeze against concerns of dilution, with some highlighting institutional ownership and potential undervaluation. The stock's volatile price action and high short interest are fueling active discussions.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending due to positive Phase 2 trial results for its cancer treatment, spurring excitement among investors. The community highlights the massive market potential and the stock's low float, which could lead to a short squeeze. However, some traders are wary of a potential offering this week, given the company's previous cash concerns.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the return to OG memes and a growing sense of anticipation for upcoming developments. Discussions revolve around community building, with members expressing strong conviction and encouraging others to join before it's "too late." The focus remains on long-term potential and a collective effort to drive the project forward.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

ATMC is trending following shareholder approval of its merger with HCYC Group, driving significant after-hours volume and price action. Community discussions highlight the stock's low float and potential for a short squeeze, with some drawing comparisons to other recent high-flying low float plays. Speculation is rampant regarding potential price targets, with many noting the possible impact of the merger on the company's valuation.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending following an analyst upgrade from Macquarie, citing strong execution and increased confidence in long-term growth. Community discussions highlight the potential for increased free cash flow and operating leverage, with some anticipating a rise towards $50. Bullish sentiment revolves around Unity's competitive ad tech, native payments, and XR technology.

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex is trending due to recent high volatility and a massive intraday surge, sparking discussions about a potential short squeeze and comparisons to other recent high-flying low float stocks. The community is actively debating its potential for a multi-day run and the influence of short sellers, while also awaiting news related to acquisitions. Some traders point to a low float and high borrow rate, suggesting a possible continued upward trajectory.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending following positive Phase 1 data for TERN-701, a potential treatment for chronic myeloid leukemia (CML), presented at the American Society of Hematology (ASH) meeting. Community discussions highlight the drug's impressive major molecular response (MMR) rate and favorable safety profile, with some speculating about a potential buyout. Analysts are raising price targets, noting TERN-701's potential to disrupt the CML treatment landscape and challenge existing market leaders.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita ($DVA) is trending amid discussions about its relationship with Akebia Therapeutics ($AKBA) and potential impacts from new kidney disease treatments, with some traders pointing to trade alerts suggesting possible bullish reversals based on oversold conditions. Community members are scrutinizing Akebia's communications and awaiting DaVita's Q3 earnings report, speculating about potential adoption of new technologies and their effect on patient outcomes. Discussions also involve the potential for mergers and acquisitions within the dialysis space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall St is expecting 0.63 EPS for $GEN Q3 [Reporting 01/29 AMC]
http://www.estimize.com/intro/gen?chart=historical&amp;metric_name=eps&amp;utm_cont